| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 國立成功大學 |
2022 |
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
Wang, M.;Yang, J.C.-H.;Mitchell, P.L.;Fang, J.;Camidge, D.R.;Nian, W.;Chiu, Chiu C.-H.;Zhou, J.;Zhao, Y.;Su, W.-C.;Yang, T.-Y.;Zhu, V.W.;Millward, Millward M.;Fan, Y.;Huang, W.-T.;Cheng, Y.;Jiang, L.;Brungs, D.;Bazhenova, L.;Lee, C.K.;Gao, B.;Xu, Y.;Hsu, W.-H.;Zheng, L.;J�nne, P.A. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
|
Drilon A.; Duruisseaux M.; Han J.-Y.; Ito M.; Falcon C.; Yang S.-R.; Murciano-Goroff Y.R.; Chen H.; Okada M.; Molina M.A.; Wislez M.; Brun P.; Dupont C.; Branden E.; Rossi G.; Schrock A.; Ali S.; Gounant V.; Magne F.; Blum T.G.; Schram A.M.; Monnet I.; JIN-YUAN SHIH; Sabari J.; P?rol M.; Zhu V.W.; Nagasaka M.; Doebele R.; Camidge D.R.; Arcila M.; Ou S.-H.I.; Moro-Sibilot D.; Rosell R.; Muscarella L.A.; Liu S.V.; Cadranel J. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; Yang J.C.-H.; JIN-YUAN SHIH; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Chih-Hsin Yang;Camidge D.R.;Yang C.-T.;Zhou J.;Guo R.;Chiu C.-H.;Chang G.-C.;Shiah H.-S.;Chen Y.;Wang C.-C.;Berz D.;Su W.-C.;Yang N.;Wang Z.;Fang J.;Chen J.;Nikolinakos P.;Lu Y.;Pan H.;Maniam A.;Bazhenova L.;Shirai K.;Jahanzeb M.;Willis M.;Masood N.;Chowhan N.;Hsia T.-C.;Jian H.;Lu S.; CHIH-HSIN YANG; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:43Z |
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer
|
Ou S.-H.I.;Zeaiter A;Golding S;Bordogna W;Han J.-Y;Chih-Hsin Yang;Tessmer A;Dansin E;De Pas T;Crino L;Duruisseaux M;Moro-Sibilot D.L;Chiappori A;Kim D.-W;De Petris L;Camidge D.R;Socinski M.A;Gandhi L;Govindan R;Shaw A.T;Gadgeel S.M; Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:43Z |
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer
|
Ou S.-H.I.;Zeaiter A;Golding S;Bordogna W;Han J.-Y;Chih-Hsin Yang;Tessmer A;Dansin E;De Pas T;Crino L;Duruisseaux M;Moro-Sibilot D.L;Chiappori A;Kim D.-W;De Petris L;Camidge D.R;Socinski M.A;Gandhi L;Govindan R;Shaw A.T;Gadgeel S.M; Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non?�small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
|
Gadgeel S.;Kotb A;Zeaiter A;Bordogna W;Golding S;Do P;L?na H;Crino L;De Castro J;Chih-Hsin Yang;Hughes B.G.M;Camidge D.R;Kim D.-W;Dingemans A.-M.C;Barlesi F;Shaw A.T;Ignatius Ou S.-H;Gandhi L; Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non?�small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria
|
Gadgeel S.;Kotb A;Zeaiter A;Bordogna W;Golding S;Do P;L?na H;Crino L;De Castro J;Chih-Hsin Yang;Hughes B.G.M;Camidge D.R;Kim D.-W;Dingemans A.-M.C;Barlesi F;Shaw A.T;Ignatius Ou S.-H;Gandhi L; Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
|
Popat S.;Kerstein D;Haney J;Gupta N;Tiseo M;Gettinger S.N;Spira A;Ghosh S;Califano R;Felip E;Morabito A;Griesinger F;Bearz A;Kim D.-W;Garcia Campelo R;Delmonte A;Gridelli C;Lee K.H;Chang G.-C;Li J.Y.-C;Hochmair M.J;Lee J.-S;Han J.-Y;Chih-Hsin Yang;Ahn M.-J;Kim H.R;Camidge D.R; Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer
|
Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J |
| 國立成功大學 |
2020 |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Yang, J.C.-H.;Camidge, D.R.;Yang, C.-T.;Zhou, J.;Guo, R.;Chiu, Chiu C.-H.;Chang, G.-C.;Shiah, H.-S.;Chen, Y.;Wang, C.-C.;Berz, D.;Su, W.-C.;Yang, N.;Wang, Z.;Fang, J.;Chen, J.;Nikolinakos, P.;Lu, Y.;Pan, H.;Maniam, A.;Bazhenova, L.;Shirai, K.;Jahanzeb, M.;Willis, M.;Masood, N.;Chowhan, N.;Hsia, T.-C.;Jian, H.;Lu, S. |
